At Biofortuna we help our customers increase the quality and availability of In Vitro Diagnostic and point of care testing.
Our services are varied, but whether we are supporting diagnostic developers, food technology experts or genomic specialists our guiding principles are the same; to form long term partnerships and become a valued extension of your team.
Operating from state-of-the art, humidity-controlled premises, and benefiting from ISO 13485 certification and FDA registration, we have a proven track record in the development, stabilisation and large-scale manufacture of PCR and LAMP molecular assays and Immunoassays.
Our services are varied, but whether we are supporting diagnostic developers, food technology experts or genomic specialists our guiding principles are the same; to form long term partnerships and become a valued extension of your team.
Operating from state-of-the art, humidity-controlled premises, and benefiting from ISO 13485 certification and FDA registration, we have a proven track record in the development, stabilisation and large-scale manufacture of PCR and LAMP molecular assays and Immunoassays.
Location: United Kingdom
Employees: 11-50
Total raised: $9.03M
Founded date: 2008
Investors 1
| Date | Name | Website |
| 19.01.2021 | Foresight ... | foresightg... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 18.08.2017 | - | $2.06M | - |
| 20.08.2013 | - | $2.04M | - |
| 11.04.2012 | - | $3.34M | - |
| 27.05.2010 | - | $1.6M | - |
Mentions in press and media 9
| Date | Title | Description |
| 08.06.2020 | QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test | QuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union. |
| 18.08.2017 | Biofortuna closes £1.6M funding round | Biofortuna closes £1.6M funding round 18-08-2017 Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has raised £1.6M in its latest funding round. Add This Share Buttons... |
| 25.01.2017 | Biofortuna expands its immunoassay development and manufacturing services | Biofortuna expands its immunoassay development and manufacturing services 25-01-2017 Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture. Add This Share Buttons The... |
| 25.01.2017 | Biofortuna expands its immunoassay development and manufacturing services | Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture. Add This Share Buttons The company has made a significant investment in its production capabilities to include ... |
| 27.07.2015 | Biofortuna launches its new approach to custom IVD manufacture and development services | Biofortuna launches its new approach to custom IVD manufacture and development services 27-07-2015 Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader por... |
| 27.07.2015 | Biofortuna launches its new approach to custom IVD manufacture and development services | Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader portfolio of custom manufacturing and development services for the IVD market. World-renowned for its ... |
| 20.08.2013 | Biofortuna Raises £1.3M in Funding | Biofortuna, a Wirral, UK-based diagnostics company, raised £1.3m in funding. Backers included all current investors Enterprise Ventures, the Foresight Group (UK), Catapult Venture Managers, Merseyside Special Investment Fund, private invest... |
| 11.04.2012 | Biofortuna Raises £2.1M in Funding | Biofortuna Limited, a Bromborough, UK-based biomedical company, recently raised £2.1m in funding. Backers include the Foresight Group (UK), which put put in £1.25m, The Merseyside Loan and Equity Fund (MSIF), EV’s Rising Stars Growth Fund (... |
| 27.05.2010 | Biofortuna Raises £1.1M from EV Tech and Catapult Venture Managers | Biofortuna Limited, a Liverpool, UK-based molecular diagnostics company, has raised £1.1m in venture capital funding. Investors in the round include EV Tech and Catapult Venture Managers. The funds will be used to launch the company’s first... |